Which has preferable earnings and valuation, LPCN or TLPH?

Lipocine has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lipocine $1.57M 11.21 -$9.63M -$1.79 N/A Talphera $1K 73,957.50 -$14.29M -$0.31 N/A

Is LPCN or TLPH more profitable?

Talphera has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets Lipocine -755.39% -64.75% -57.62% Talphera N/A -92.98% -53.22%

Does the media prefer LPCN or TLPH?

In the previous week, Talphera had 3 more articles in the media than Lipocine. MarketBeat recorded 5 mentions for Talphera and 2 mentions for Lipocine. Lipocine's average media sentiment score of 1.00 beat Talphera's score of 0.12 indicating that Lipocine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Talphera 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend LPCN or SPRO?

Lipocine currently has a consensus price target of $15.00, indicating a potential upside of 602.58%. Given Lipocine's stronger consensus rating and higher probable upside, research analysts clearly believe Lipocine is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer LPCN or SPRO?

In the previous week, Spero Therapeutics had 2 more articles in the media than Lipocine. MarketBeat recorded 4 mentions for Spero Therapeutics and 2 mentions for Lipocine. Lipocine's average media sentiment score of 1.00 beat Spero Therapeutics' score of 0.00 indicating that Lipocine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spero Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, LPCN or CLNN?

Lipocine has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lipocine $1.57M 11.21 -$9.63M -$1.79 N/A Clene $200K 299.24 -$26.17M -$3.20 N/A

Is LPCN or CLNN more profitable?

Lipocine has a net margin of -755.39% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Lipocine's return on equity. Company Net Margins Return on Equity Return on Assets Lipocine -755.39% -64.75% -57.62% Clene -25,009.70% N/A -137.98%

Does the media prefer LPCN or CLNN?

In the previous week, Clene had 1 more articles in the media than Lipocine. MarketBeat recorded 3 mentions for Clene and 2 mentions for Lipocine. Lipocine's average media sentiment score of 1.00 beat Clene's score of 0.00 indicating that Lipocine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Clene 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, LPCN or MNOV?

Lipocine has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lipocine $1.57M 11.21 -$9.63M -$1.79 N/A MediciNova $596.64K 110.13 -$12M -$0.23 N/A

Is LPCN or MNOV more profitable?

Lipocine has a net margin of -755.39% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Lipocine's return on equity. Company Net Margins Return on Equity Return on Assets Lipocine -755.39% -64.75% -57.62% MediciNova -1,962.98% -27.28% -25.24%

Does the media favor LPCN or MNOV?

In the previous week, Lipocine and Lipocine both had 2 articles in the media. Lipocine's average media sentiment score of 1.00 beat MediciNova's score of 0.00 indicating that Lipocine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediciNova 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CING or LPCN more profitable?

Cingulate has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Cingulate N/A -365.15% -158.55% Lipocine -755.39% -64.75% -57.62%

Lipocine (LPCN) Competitors

$2.13 +0.01 (+0.23%)

As of 10:58 AM Eastern

Compare

LPCN vs. TLPH, SPRO, CLNN, MNOV, and CING

Should you buy Lipocine stock or one of its competitors? MarketBeat compares Lipocine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lipocine include Talphera (TLPH), Spero Therapeutics (SPRO), Clene (CLNN), MediciNova (MNOV), and Cingulate (CING). These companies are all part of the "pharmaceuticals" industry.

How does Lipocine compare to Talphera?

Lipocine (NASDAQ:LPCN) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Lipocine currently has a consensus target price of $15.00, indicating a potential upside of 602.58%. Talphera has a consensus target price of $3.00, indicating a potential upside of 110.53%. Given Lipocine's stronger consensus rating and higher possible upside, research analysts clearly believe Lipocine is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

9.1% of Lipocine shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 4.7% of Lipocine shares are owned by company insiders. Comparatively, 3.5% of Talphera shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Talphera has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-755.39%	-64.75%	-57.62%
Talphera	N/A	-92.98%	-53.22%

Lipocine has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market. Comparatively, Talphera has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

In the previous week, Talphera had 3 more articles in the media than Lipocine. MarketBeat recorded 5 mentions for Talphera and 2 mentions for Lipocine. Lipocine's average media sentiment score of 1.00 beat Talphera's score of 0.12 indicating that Lipocine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Talphera	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lipocine has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.57M	11.21	-$9.63M	-$1.79	N/A
Talphera	$1K	73,957.50	-$14.29M	-$0.31	N/A

Summary

Lipocine beats Talphera on 9 of the 17 factors compared between the two stocks.

How does Lipocine compare to Spero Therapeutics?

Lipocine (NASDAQ:LPCN) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Lipocine has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market.

Spero Therapeutics has a net margin of 24.90% compared to Lipocine's net margin of -755.39%. Spero Therapeutics' return on equity of 35.58% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-755.39%	-64.75%	-57.62%
Spero Therapeutics	24.90%	35.58%	24.95%

In the previous week, Spero Therapeutics had 2 more articles in the media than Lipocine. MarketBeat recorded 4 mentions for Spero Therapeutics and 2 mentions for Lipocine. Lipocine's average media sentiment score of 1.00 beat Spero Therapeutics' score of 0.00 indicating that Lipocine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spero Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spero Therapeutics has higher revenue and earnings than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.57M	11.21	-$9.63M	-$1.79	N/A
Spero Therapeutics	$66.80M	1.09	$8.57M	$0.24	5.23

Lipocine currently has a consensus price target of $15.00, indicating a potential upside of 602.58%. Given Lipocine's stronger consensus rating and higher probable upside, research analysts clearly believe Lipocine is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

9.1% of Lipocine shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 4.7% of Lipocine shares are owned by insiders. Comparatively, 2.9% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Spero Therapeutics beats Lipocine on 10 of the 16 factors compared between the two stocks.

How does Lipocine compare to Clene?

Lipocine (NASDAQ:LPCN) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Lipocine has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.57M	11.21	-$9.63M	-$1.79	N/A
Clene	$200K	299.24	-$26.17M	-$3.20	N/A

Lipocine has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, Clene has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Lipocine currently has a consensus target price of $15.00, indicating a potential upside of 602.58%. Clene has a consensus target price of $33.25, indicating a potential upside of 610.01%. Given Clene's stronger consensus rating and higher probable upside, analysts plainly believe Clene is more favorable than Lipocine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Lipocine has a net margin of -755.39% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-755.39%	-64.75%	-57.62%
Clene	-25,009.70%	N/A	-137.98%

In the previous week, Clene had 1 more articles in the media than Lipocine. MarketBeat recorded 3 mentions for Clene and 2 mentions for Lipocine. Lipocine's average media sentiment score of 1.00 beat Clene's score of 0.00 indicating that Lipocine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Clene	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.1% of Lipocine shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 4.7% of Lipocine shares are owned by company insiders. Comparatively, 28.3% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Clene beats Lipocine on 9 of the 17 factors compared between the two stocks.

How does Lipocine compare to MediciNova?

Lipocine (NASDAQ:LPCN) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Lipocine currently has a consensus price target of $15.00, indicating a potential upside of 602.58%. MediciNova has a consensus price target of $8.33, indicating a potential upside of 524.22%. Given Lipocine's higher possible upside, equities analysts clearly believe Lipocine is more favorable than MediciNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

9.1% of Lipocine shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 4.7% of Lipocine shares are owned by insiders. Comparatively, 14.0% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Lipocine has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

Lipocine has a net margin of -755.39% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-755.39%	-64.75%	-57.62%
MediciNova	-1,962.98%	-27.28%	-25.24%

In the previous week, Lipocine and Lipocine both had 2 articles in the media. Lipocine's average media sentiment score of 1.00 beat MediciNova's score of 0.00 indicating that Lipocine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MediciNova	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lipocine has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.57M	11.21	-$9.63M	-$1.79	N/A
MediciNova	$596.64K	110.13	-$12M	-$0.23	N/A

Summary

MediciNova beats Lipocine on 9 of the 15 factors compared between the two stocks.

How does Lipocine compare to Cingulate?

Cingulate (NASDAQ:CING) and Lipocine (NASDAQ:LPCN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

41.3% of Cingulate shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 5.3% of Cingulate shares are held by insiders. Comparatively, 4.7% of Lipocine shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cingulate presently has a consensus target price of $27.33, indicating a potential upside of 420.14%. Lipocine has a consensus target price of $15.00, indicating a potential upside of 602.58%. Given Lipocine's higher probable upside, analysts plainly believe Lipocine is more favorable than Cingulate.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Lipocine had 2 more articles in the media than Cingulate. MarketBeat recorded 2 mentions for Lipocine and 0 mentions for Cingulate. Lipocine's average media sentiment score of 1.00 beat Cingulate's score of 0.00 indicating that Lipocine is being referred to more favorably in the news media.

Company	Overall Sentiment
Cingulate	Neutral
Lipocine	Positive

Cingulate has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-365.15%	-158.55%
Lipocine	-755.39%	-64.75%	-57.62%

Lipocine has higher revenue and earnings than Cingulate. Cingulate is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A
Lipocine	$1.57M	11.21	-$9.63M	-$1.79	N/A

Cingulate has a beta of -0.9, indicating that its share price is 190% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

Summary

Lipocine beats Cingulate on 11 of the 16 factors compared between the two stocks.

Get Lipocine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LPCN vs. The Competition

Export

Metric	Lipocine	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$17.60M	$11.88B	$7.03B	$12.96B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-1.20	788.46	269.91	24.87
Price / Sales	11.21	969.81	654.69	108.21
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	0.82	10.37	11.40	6.45
Net Income	-$9.63M	$2.77B	$3.45B	$347.50M
7 Day Performance	1.18%	2.26%	3.66%	3.77%
1 Month Performance	-11.41%	-1.28%	-0.49%	-0.40%
1 Year Performance	-27.13%	191.26%	77.51%	23.55%

Lipocine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LPCN Lipocine	3.3182 of 5 stars	$2.14 +0.2%	$15.00 +602.6%	-27.3%	$17.60M	$1.57M	N/A	10	Positive News Earnings Report
TLPH Talphera	2.3706 of 5 stars	$1.36 +2.3%	$3.00 +120.6%	+249.2%	$69.03M	$30K	N/A	19	Upcoming Earnings Analyst Upgrade
SPRO Spero Therapeutics	0.9786 of 5 stars	$1.23 +7.0%	N/A	-42.5%	$66.59M	$66.80M	5.13	150	Upcoming Earnings
CLNN Clene	2.0641 of 5 stars	$5.28 +1.7%	$33.25 +529.7%	+43.5%	$66.32M	$200K	N/A	100	News Coverage Upcoming Earnings
MNOV MediciNova	1.4015 of 5 stars	$1.30 -2.3%	$8.33 +541.0%	-0.7%	$65.46M	$410K	N/A	10	Upcoming Earnings Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LPCN) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lipocine (LPCN) Competitors